Cetrorelix was also evaluated in five patients with advanced carcinoma of the prostate and paraplegia due to metastatic compression of spinal cord, who could not be treated with LH-RH agonists because of the risk of “flare”34. Here, GNRH1 is linked to prostate carcinoma.